S.-based studies are needed to determine the long-term clinical outcomes from the use of tomosynthesis, including breast cancer stage distribution, recurrent or second breast cancers, and mortality rates. Lee suggests, “It probably doesn’t replace supplemental screening with ultrasound for women with dense breasts or screening with MRI for women at high risk for breast cancer.” There’s a slightly higher radiation dose for 3D relative to 2D mammography, but the dose is well below the acceptable limits defined by the FDA, notes Gregory K.
Three prospective, population-based European trials revealed overall favorable findings for DBT.
In particular, compared with DM, tomosynthesis detected about 2 to 3 more cancers per 1000 women.
Synthetic 2D mammography, when compared with DM-DBT and DM alone, “showed an additional improved clinical performance in regards to false positives and callbacks, while maintaining cancer detection rates,” comments Dr. “The synthetic 2D mammogram is suitable for interpretation, while forgoing the additional radiation exposure to obtain a readable 2D image.
It’s a potential game-changer.” What to watch out for in DBT As the use of DBT as a screening tool continues to grow, clinicians should be aware of the potential concerns and limitations surrounding this technology.